Live Breaking News & Updates on Darden Powell|Page 2

Stay updated with breaking news from Darden powell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences ....

United States , United Kingdom , Pierre Fabre , Sumitovant Biopharma , Jim Robinson , Maya Frutiger , Eric Ducournau , Alana Darden Powell , Anne Kerveillant , Urovant Sciences Gmb , Media Relations Pf Pharmaceuticals Direction , Corporate Communications , Pierre Fabre Group , Urovant Sciences , Sumitovant Biopharma Ltd , Head Of Corporate Communications , Pierre Fabre Foundation , Overactive Bladder , Europe Economic Area , Sciences Gmbh , European Economic Area , Sub Saharan Africa , Eastern European , Chief Executive Officer , Benign Prostatic Hyperplasia , Sumitomo Pharma ,

Urovant Sciences, Inc.: Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium ....

United States , Sumitovant Biopharma , Sumitomo Pharma , Maya Frutiger , Alana Darden Powell , David Staskin , Jeffrey Frankel , Drug Administration , American Urological Association , Urovant Sciences Gmb , Seattle Urology Research Center , Corporate Communications , Tufts University School Of Medicine , Us Public Health , Urovant Sciences , Sumitovant Biopharma Ltd , Head Of Corporate Communications , Patient Global Impression , New Orleans , Sef Kurstjens , Executive Vice President , Chief Medical Officer , Medical Director , Term Efficacy , Overactive Bladder , Associate Professor ,

Urovant Sciences, Inc.: Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the ....

United States , Sumitovant Biopharma , Kenneth Peters , Sumitomo Pharma , Maya Frutiger , Alana Darden Powell , Department Of Urology At Beaumont Hospital , American Urological Association , Urovant Sciences Gmb , Corporate Communications , Us Public Health , Pelvic Health Center , Urovant Sciences , Sumitovant Biopharma Ltd , Head Of Corporate Communications , Plenary Presentation , New Orleans , Principal Investigator , Beaumont Hospital , Royal Oak , Medical Director , Beaumont Women , Oakland University William Beaumont School , Sef Kurstjens , Executive Vice President , Chief Medical Officer ,

Urovant Sciences, Inc.: Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA in Dry and Wet Overactive Bladder Populations

Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears ....

United States , Sumitovant Biopharma , Sumitomo Pharma , Salim Mujais , Maya Frutiger , Alana Darden Powell , Jeffrey Frankel , International Journal Of Clinical Practice , Aboutsumitovant Biopharma Ltd , Urovant Sciences Gmb , Seattle Urology Research Center , Sumitomo Pharma Co Ltd , Corporate Communications , Urovant Sciences , Sumitovant Biopharma Ltd , Head Of Corporate Communications , Clinical Development , International Journal , Wet Overactive Bladder , Subgroup Analysis , Medical Director , Seattle Urology Research , Senior Vice President Clinical Development , Product Information , Urovant Sciences Gmbh , Darden Powell ,

Urovant Sciences, Inc.: Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management

Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA's role as an effective treatment option for overactive bladder (OAB) ....

United States , Sumitomo Dainippon Pharma , Sumitovant Biopharma , Maya Frutiger , Alana Darden Powell , Cornelia Haag Molkenteller , Jeffrey Frankel , Aboutsumitovant Biopharma Ltd , Dainippon Pharmaceutical Co Ltd , Seattle Urology Research Center , Corporate Communications , Sumitomo Dainippon Pharma Co Ltd , Urovant Sciences , Sumitomo Pharmaceuticals Co Ltd , Sumitovant Biopharma Ltd , Clinical Risk Management , Seattle Urology Research , Chief Medical Officer , Product Information , Dainippon Pharma , Darden Powell ,